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Summary Information about occurrence of testicular cancer (TC) in relatives of TC patients has been
collected using questionnaires from 797 out of 922 consecutive Norwegian and 178 out of 237 Swedish patients
with TC seen at the Norwegian Radium Hospital and the University Hospital Lund in Sweden during 1981-
91. Fifty-one Norwegian and five Swedish patients had a relative with confirmed TC. Thus, 51/922 (5.5%) of
the Norwegian and 5/237 (2.1%) of the Swedish patients treated during the time interval investigated were
considered to have familial TC. Thirty-two of the patients had an affected first-degree relative. Expected
numbers of cancers in the relatives were computed from data in the Norwegian and Swedish Cancer Registries.
Standardised incidence ratios (SIRs) were taken as observed numbers of TC/expected numbers of TC in the
relatives. The SIR for brothers was 10.2 (95% confidence interval 6.22-15.77). SIR for fathers was 4.3 (1.6-
9.3) and for sons 5.7 (0.7-23.2). The point estimate for the risk to brothers in the Norwegian part of the
sample to develop TC by the age of 60 was 4.1% (95%CI 1.7-6.6%). This study indicates that genetic factors
may be of greater importance in TC than previously assumed. Patients with familial testicular cancer had
bilateral tumours more often than sporadic cases (9.8% bilaterality in familial vs 2.8% in sporadic cases,
P=0.02). For patients with seminoma age of onset was lower in familial than in sporadic cases (32.9 vs 37.6
years, P=0.06). In father-son pairs, there was a statistically significant earlier age of diagnosis in the
generation of sons (28.8 years vs 44.9 years, P=0.04). The prevalence of undescended testis (UDT) did not
seem to be higher in familial than in sporadic TC (8.2% in familial TC and 13.3% in sporadic cases). This may
indicate that different factors are of importance for the development of familial TC and UDT.
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Familial testicular cancer (TC) although rare, is a well
documented entity. There are numerous reports in the
literature of families with two or more affected members.
Two reports have estimated the relative risk to first-degree
relatives of TC cases to be between 6 and 10 (Tollerud et al.,
1985; Forman et al., 1992). This estimate is considerably
higher than that for most common cancers in which it rarely
exceeds 4 (Forman et al., 1992). The proportion of TC that is
familial is, however, considered to be very low (0.2-2.2% of
cases) (Dieckmann et al., 1987).
We have established a database on all TC patients treated
at the Norwegian Radium Hospital, Oslo, Norway and
University Hospital Lund in Sweden over more than 10
years. In this paper, we give details ofclinical data and family
history of all evaluable patients, compare clinical character-
istics of patients with familial and sporadic TC and estimate
the relative risk to first-degree relatives of TC patients.
Materials and methods
The Norwegian patient cohort consists of 895 consecutive
patients referred for post-orchiectomy treatment for testicular
germ cell tumour (TC) at the Norwegian Radium Hospital
(NRH) from January 1981 to June 1991 and 27 patients
treated at Haukeland University Hospital in Bergen in the
same period. The NRH today serves as the only oncology
centre giving post-orchiectomy treatment to approximately
half the Norwegian population of 4.2 million. During the
early 1980s, when oncology services were being established in
other parts of the country, the NRH also treated a major
proportion of TC patients from other areas. We have,
however, no indication of a selective referral to the NRH on
the basis of positive family history of TC or other cancers.
We obtained information about cancer in the families of
all surviving patients who could be located by means of a
questionnaire. Patients were asked to list the year of birth
and year of cancer diagnosis/year of death if applicable for
all first-degree relatives and grandparents. In addition, we
asked for cases of testicular cancer in more distant relatives.
Using the same methods, family history of cancer was
obtained from all available patients treated at the University
Hospital Lund in southern Sweden during the same period
(n=237). This hospital gives oncological treatment to all TC
cases seen in a defined geographical region in southern
Sweden.
As this study deals with the number of families of
testicular cancer patients rather than the number of
patients, adjustment was made for double ascertainment of
families. This occurred in eight Norwegian and two Swedish
families, which was ascertained through two members with
TC diagnosed during the accrual period. Members of these
families were counted twice in the calculations of standar-
dized incidence ratios (SIRs).
In Norway and Sweden the reporting of all malignant
diseases to national cancer registries has been mandatory
since the establishment of the registries in 1953 and 1958
respectively. All cancers among relatives stated in the
questionnaire were checked against these cancer registries.
Inaccuracy in the cancer localisation recorded by the patients
was corrected. For testicular cancers occurring before the
establishment of the registries, confirmation of the diagnosis
and corrections were carried out on the basis of hospital
records, pathology reports and/or death certificates. All
calculations in this report include only relatives with
confirmed invasive cancers.
Data from the questionnaires were used to calculate SIRs
for first-degree relatives. For these calculations, only cancers
diagnosed after 1953 in Norway and 1958 in Sweden were
included. Expected numbers of cancers in the relatives were
calculated separately for the Norwegian and Swedish
population. For the calculations of SIRs relatives were
assumed to be at risk from the establishment of the Cancer
Registry. A standard life-table procedure was used to
compute person-years at risk and the expected number of
cancers from the establishment of the Cancer Registries to
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Table I Details of familial cases
Family Proband Relative with testicular cancer
number Histology Age at onset Histology Age ofonset
n-16a Seminoma 32 MZ twin
MTU
TD
Seminoma
Seminoma
Seminoma
MTI (combined
tumour)
MTT
Seminoma
Bilateral synchronous
seminoma
Seminoma
MTT
MTT
Seminoma
MTI
MTI
Seminoma
MTI (combined
tumour)
MTI
MTI (combined
tumour)
MTU
Seminoma
Bilateral asynchronous
seminoma
Seminoma
MTI (combined
tumour)
Seminoma
Seminoma
MTI (combined
tumour)
Seminoma
Seminoma
MTI (combined
tumour)
Seminoma
Seminoma
Seminoma
MTU and MTI
Bilateral
asynchronous
seminoma
MTU
Seminoma
Seminoma
MTI
21
44
29
58
47
29
46
33
33
41
19
43
33
29
20
44
40
19
29
39
25
25 and 30
36
31
28
33
26
32
33
28
35
29
72
18 and 22
28 and 33
34
33
53
28
Brother
Brother
Brother
Brother
Brother
Brother
Brother
Brother
Brother
Brother
Brother
Brother
Brother
Brother
Father
Father
Father
Father
Father
Father
Father
Paternal
grandfather
Paternal
grandfather
Paternal uncle
Maternal uncle
Maternal uncle
Son of mother's
sister
Maternal uncle
Maternal uncle
Maternal uncle
Paternal uncle
Son of brother
Son of sister
Son of brother
Double cousin
Son of mother's
sister
Son of mother's
sister
Maternal uncle
Son of father's
brother
Son of mother's
brother
Son of father's
brother
Son of mother's
maternal half-
brother
Bilateral synchronous
seminoma
MTI
Spermatocytic
seminoma
Malignant tumour
not specified
(non-seminoma) and
seminoma
Seminoma
Seminoma
MTI (combined
tumour)
Seminoma
MTU
Seminoma
Seminoma
MTU
Seminoma
Seminoma
Seminoma
MTU
Seminoma
(Chronic lymphatic
leukaemia)
Chorionic+embryonic
carcinoma
Seminoma (lung
cancer)
Seminoma
Teratoma (diagnosis
1956)
Seminoma
Seminoma
(leiomyosarcoma)
Seminoma
(prostate cancer)
Seminoma
Bilateral
asynchronous
seminoma
Teratoma (diagnosis
1954)
Seminoma
Seminoma
Malignant embryonal
tumour
(diagnosis 1945)
MTU
Carcinoma
not further specified
(diagnosis 1952)
Extragonadal MTU
MTU
MTI
Seminoma
MTI
MTU
Not confirmed
MTU
MTI
Seminoma
Seminoma
(anal cancer)
n~la
n_2a
n-ll
n-14
n-21
n-23
n-30
n-31
n-32
n-34
n-46
n-48b
n-51
n-63b
n-3a
n-6b
n-7b
n-9
n-19
n-38
n-4la
n-4
n-13
n-8
n-15
n-43
n-44a
n-49
32
30
58
28 and 35
52
49
25
30
31
28
48
34
29
30
33
45
44
59
48
44
36
53
27
49
41
26 and 42
35
36
47
25
32
25
28
16
29
24
26
32
38
37
33
33
n-52
n-59
n-18
n-25
n-62a
n-42
n-10
n-17
n-26a
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Table I cont
Family Proband Relative with testicular cancer
number Histology Age at onset Histology Age ofonset
n-29 Seminoma 26 Patients share MTI 26
paternal great-
great grandfather
n-24 Seminoma 34 See Figure 1 Seminoma 34
See Figure 1 MTI 17
n-45 Seminoma 42 Son of son of MTI 20
(tongue cancer) mother's brother
S-la Seminoma 40 Brother Seminoma 37
s-2a Seminoma 28 Brother Seminoma 25
s-3 MTU 24 Father Seminoma 44
a Doubly ascertained families. MTU, malignant teratoma undifferentiated; MTI, malignant teratoma intermediate; MTT, malignant teratoma
trophoblastic; TD, Teratoma differentiated. These families are not included in the calculation of SIRs. Families are marked n (Norwegian) or s
(Swedish).
the end of 1992. The algorithm calculates the expected
number of cancers based on the incidence rates by age, sex,
and birth cohort (Borresen et al., 1990). Relatives were
assumed to be at risk until they developed a first cancer at
any site, until death occurred or up to January 1, 1993,
whichever occurred first. Thus, recognising that the treatment
of the first cancer may influence an individual's risk of a
second cancer, second cancers, including a TC in a father
previously treated for leukaemia (family n-7), were ignored.
SIRs were calculated as the ratio of observed/expected
number of cancers and 95% confidence intervals (CIs) were
calculated assuming a Poisson distribution of the observed
cancers.
Estimation of the cumulative risk to brothers of cases of
developing TC was calculated using the life-table method
with the BMDP-lL statistical software package (Dixon et al.,
1990).
Results
Response rates
A total of 816/869 (93.9%) Norwegian and 178/211 (84.3%)
Swedish patients who received the questionnaire responded.
A total of 975 of the returned questionnaires contained
family information. For the Norwegian patients in whom
family history was not available from the questionnaire, the
hospital records were checked for the presence of testicular
cancer in the relatives. Thus, we have information about
testicular cancers in the families of 93.3% (1081/1159) of all
eligible patients, of which the great majority have been
treated at the two institutions during a period of more than
10 years. Of the 125 Norwegian and 59 Swedish patients for
whom family information was not available from the
questionnaire, 69 patients had died, 13 patients had
emigrated or could not be located, and five patients were
adopted. For the remaining 97 patients questionnaires were
not returned (n=71) or contained no family history (n=26,
including five patients who refused to participate in the
investigation).
Description of the families
Fifty-one out of 922 (5.5%) of the Norwegian and 5/237
(2.1%) of the Swedish patients could be classified as familial
cases (Table I). Thus, the frequency of familial cases was
4.8%. About half of the familial cases had an affected first-
degree relative (32/1159=2.8%). The percentage of patients
with an affected first-degree relative was similar in the
Norwegian and Swedish patients (27/922 =2.9% and 5/
237=2.1% respectively). Only Norwegian patients reported
TC in more distant relatives (n =24).
The 1081 patients belonged to 1071 families, of which 46
were defined as testicular cancer families with two or more
affected relatives. Forty-three families had two affected
members and three families had three affected members
(families n-10, n-24 and n-43). In addition, family n-10
possibly had a fourth affected member in that a maternal
uncle was reported to have had TC in 1948. This cancer is,
however, not confirmed. The pedigrees of the three families
with three affected members are shown in Figure 1. Details of
the familial cases are given in Table I.
In the questionnaire 29 patients reported a first-degree
relative, 15 patients a second-degree relative, seven patients a
cousin, and three patients a more distant relative with germ
cell tumour, including one proband who reported both an
uncle and a cousin with the disease. The brother pairs include
one pair of monozygotic twins, in whom three seminomas
were discovered simultaneously. No brother had childhood
TC. SIRs for first-degree relatives are given in Table II. Two
patients reported a paternal grandfather with TC. Both
grandfathers had the disease before 1953. Eight patients had
an affected uncle and four patients an affected nephew
(including one nephew with extragonadal germ cell tumour,
Table I). In addition, one proband had an affected double
cousin. Seven patients had one affected first cousin (Table T).
In an additional patient we confirmed the presence of two
maternal cousins (family n-10) with the disease and, in family
n-30, the son of the mother's brother had TC during 1993. A
final three patients had one or more distant relatives with TC
(Table I).
Family n-10
Family n-24
Figure 1 Families with more than two cases of testicular cancer.
Closed squares denote affected males, arrows indicate probands.
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Table II Standardised incidence ratio for testicular cancer in first-degree relatives of testicular cancer patients.
Testicular cancers
Person-
Number of years at Observed Expected
relatives risk number number SIR (95% CI)
Sons 661 10547 2 0.31 6.45 (0.65-23.23)
Brothers 993 32489 20 1.96 10.20 (6.22-15.77)
Fathers 889 28200 6 1.41 4.26 (1.56-9.29)
All male first-
degree relatives 2543 71236 28 3.68 7.61 (5.05-11.01)
In addition to the familial cases ascertained through the
questionnaire, familial TC is known to have occurred in four
Norwegian families. One brother was diagnosed with
testicular cancer during 1993 (family n-63, Table I) and two
patients who have not answered the questionnaire are known
to have a father and a brother respectively, with the disease
(families n-6 and n-48, Table I). Finally, twin brothers who
are second cousins of a proband that did not respond to the
questionnaire both had TC during 1994 (family n-53). The
latter cases occurred after the completion of the data analysis
and the proband is included as a sporadic case in all
calculations.
In the Norwegian data set we calculated the cumulative
risk to brothers of having TC (Figure 2). The point estimate
of the risk at 50 years of age was 2.8% (95% CI 1.2-4.4%)
rising to 4.1% (95% CI 1.7-6.6%) at age 60. The calculated
increase in risk between ages 50 and 60 is based on only two
cases, one of which developed a spermatocytic seminoma at
age 58.
Clinical details of the Norwegian familial cases
Bilaterality Five out of 51 probands with familial TC had
bilateral tumours (9.8%, 95% CI 3.1-22.9%). Four out of
five contralateral tumours were seminomas (two synchronous
and two asynchronous). Correspondingly, 24/871 (2.8%,
95% CI 1.8-4.1%) patients with sporadic TC had contra-
lateral germ cell tumours. Thus, the proportion of patients
with bilateral tumours was significantly higher in familial
than sporadic TC (P=0.02, Fisher's exact one-tailed test).
Histology There were 33 pure seminomas (58.9%) including
one spermatocytic seminoma, six combined tumours and 17
pure non-seminomas among the probands with familial
tumours. Among the sporadic cases, 448/892 (50.2%)
tumours with known histological subclassification were
5.0
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c
0
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._
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0
._
40
-0 1.C
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brothers '
at risk
Figure 2
Norwegia
P(Testicular cancerlBrother has TC)
seminomas. Counting combined tumours with the non-
seminomas the distribution of histological types in the
probands is not different from that of the non-familial cases
(chi-square with Yates' correction 1.27, P=0.26).
Age of diagnosis The median age of the probands with
familial tumours at (first) orchiectomy was 32.6 years (range
17.9-71.8 years). Median age in the group of sporadic cases
was 32.7 years (14.5-81.8 years). The age of the probands
that were fathers/uncles (n=6) was 45.8 years (range 28.8-
71.8 years), while the age of remaining probands (n=45) was
31.7 years (range 17.9-58.1 years). This difference is
statistically significant (P=0.02, Mann-Whitney U-test).
The age distribution of the probands with familial tumours
(excluding the fathers and uncles) was not significantly
different from that of sporadic cases (P=0.57, Mann-
Whitney U-test).
As there were slightly more seminomas in the probands
with familial TC than in the sporadic cases, age at
orchiectomy was calculated separately for each histological
subgroup. Median age for seminomas was lower in the
familial cases when excluding probands that were fathers or
uncles than in sporadic cases (32.9 vs 37.6 years) and
somewhat higher in the non-seminomas (29.2 vs 28.1 years).
The difference in median age of onset was of borderline
statistical significance in seminomas (P=0.06, Mann-
Whitney U-test).
In the familial cases there are seven father-son pairs. The
sons had a lower median age at orchiectomy (28.8 years,
range 19.0-44.2 years) than their fathers (44.9 years, range
35.9-59.2 years). This difference was statistically significant
(P=0.04, one-tailed Wilcoxon signed-rank test for paired
data).
Undescended testis (UDT) The prevalence of UDT was
calculated from information obtained by questionnaire and/
or patients records. UDT had been present in 4/49 (8.2%)
probands with familial TC and in 107/804 (13.3%) sporadic
cases with known status as to testicular descent. The
difference is not statistically significant.
Discussion
Our estimate of the proportion of familial cases in TC was
4.8%. The proportion of familial cases in the Norwegian part
of the study is considerably higher than in the Swedish part.
The discrepancy is due to the absence of testicular cancers in
distant relatives in the Swedish patients and the presence of
such cases in Norway. It seems unlikely that there are
separate risk factors in the two countries restricting the excess
risk in Swedes to first-degree relatives, and we believe the
discrepancy may be due to underreporting of cases in distant
relatives in Sweden. Alternatively, the abscence of affected
0 18 36 54 72 90 distant relatives in Sweden could be a chance finding owing
Age to the smaller number of relatives studied.
909 879 530 158 17 0 Even when familial TC is defined as affected first-degree
relatives only, our estimate (2.8%) is somewhat higher than
reported in the literature (Dieckmann et al., 1987; Forman et
Probability of testicular cancer in brothers of al., 1992; Tollerud et al., 1985). However, the discrepancy
tn testicular cancer patients. may be explained by differences in study design and inFamilial testicular cancer in Norway and southern Sweden
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definition of familial TC. In contrast to other investigators,
we have scored cases as familial if the relative also had a
diagnosis of TC after the date of diagnosis in the proband. In
addition, we may have a longer and more complete follow-up
of the families than do other investigators owing to the
structure of the oncology service in Norway and Sweden. In
Norway we have a nationwide follow-up of familial TC and
it is unlikely that there has been a familial TC case since 1990
of which we are not aware. Given that most TC families have
two affected members, studies that sample incident cases from
a relatively short period will identify only approximately half
the familial cases.
In order to obtain an accurate estimate of the proportion
of familial cases, we have checked all patients' records for
notes regarding a positive family history of TC. Patients
identified as familial cases in this way are included in the
calculation of the proportion of familial cases if the diagnosis
in the relative could be verified. However, the records are not
likely to contain accurate information about second- and
third-degree relatives. By checking the records, we did find
approximately the same proportion of familial cases as
expected from the family questionnaires. Thus, we have no
reason to believe there is a large overreporting of familial
cases. On the contrary, we believe the estimates represent
minimum figures as to the true incidence of familial TC.
Although not directly comparable, our estimate of the
absolute risk to brothers is almost the same as that presented
by Forman et al. (1992) at 50 years. Forman et al. did not
include brothers of more than 50 years of age. Our data,
although based on very few cases, suggest that the increased
risk to family members may not be limited to individuals less
than 50 years of age.
It is not known whether the familial risk in TC is due to
genetic and/or environmental factors. Three independent
studies indicate that the relative risk in TC is between 6
and 10 (Tollerud et al., 1985; Forman et al., 1992). In most
common cancers the relative risk to first-degree relatives has
been found to be between 2 and 5 (Forman et al., 1992).
Simulation studies have indicated that large relative risks to
family members of cases in the absence of genetic
susceptibility must be due to very potent shared environ-
mental risk factors (Khoury et al., 1988), and such factors
have not been identified in testicular cancer. Thus, the size of
the relative risk seen here may be taken as an indication of
the importance of genetic factors in testicular cancer.
The mode of inheritance in familial TC is unknown. The
consistent reporting of father-son pairs makes a significant
contribution of X-linked genes unlikely. The pattern of
familial clustering indicates increased relative risks both in
fathers and brothers of cases, the risk being higher in
brothers than in fathers. This is the expected result if
maternal factors contributed to the risk (constitutional
factor in the mother, recessive major gene effects), but is
also compatible with models that imply a dominant gene with
the addition of common environmental effects acting in the
younger generation.
Owing to the family structure of this population with a
preponderance of small families, a significant proportion of
cases cannot be scored as familial defined on the basis of TC
in close relatives. The 797 Norwegian patients reported 909
brothers, that is on average 1.14 brothers per case. A total of
277 patients did not have a brother and 290 had only one
brother. Thus, less that 30% of the families are expected to
have three or more brothers (including the proband).
Similarly, a significant proportion of patients did not have
sons who have lived through a substantial proportion of their
period at risk for TC. If the disease is (in part) caused by
recessive gene(s) or dominant gene(s) with low penetrance,
then the importance of these genetic factors may be much
greater than anticipated at first sight, and the proportion of
cases attributable to genetic factors may be greater than
usually assumed.
We found a slight overrepresentation of seminomas in the
familial cases, although this was not statistically significant.
Apart from possibly being of biological significance, it may
be a result of ascertainment biases or differential fertility in
seminomas as compared with non-seminomas. At least in
former generations, in whom the lethality of non-seminomas
was greater than of seminomas, this factor may have been of
importance. Interestingly, one member of a brother pair had
a spermatocytic seminoma. The occurrence of this rare
tumour in a brother of a TC patient indicates that
spermatocytic seminomas, although believed to be different
from other germ cell tumours in terms of pathogenesis, may
share aetiological factors with the other germ cell tumours.
Our finding of a greater proportion of bilateral tumours in
familial as compared with sporadic TC is in agreement with
published reports (Dieckmann et al., 1987; Forman et al.,
1992). The finding strengthens the argument that bilateral
cases may be genetic.
The point estimate of the SIR is greater in the younger
generation, the risk to brothers being larger than the risk to
fathers. Data are too sparse to allow estimation of risk to
sons. The increased SIR in the younger generation may
indicate genetic anticipation. This phenomenon has pre-
viously been suggested to be present in TC (Raghavan et al.,
1980). If such a mechanism was operating, this would give an
indication of what sort of predisposition gene might be
involved. Our finding that sons had an earlier age of onset
than fathers in affected father-son pairs and that the age of
onset in the father-uncle generation was higher than in the
remaining familial cases supports the anticipation theory. The
former also has been observed previously (Forman et al.,
1992).
However, our findings may be the result of ascertainment
bias possibly in combination with reduced fertility in the
parent generation. The latter is known to mimic genetic
anticipation. The effect is produced because only patients
with late onset are able to reproduce. This would be relevant
for all TC patients but especially for patients with non-
seminomas in the 1950s- 1970s. During this time period, non-
seminomas, which occur on average 10 years earlier than the
seminomas, had a much worse prognosis than seminomas
with respect both to survival and chance of reproduction.
If familial cases are indeed genetically predisposed to TC
we would expect them to have an early age of onset
compared with sporadic cases according to the two-hit
model for tumorigenesis originally proposed by Knudson in
1971. This was found by Forman et al. (1992) in TC patients
from the UK when excluding the older generation to correct
for ascertainment bias. In the present data set we found the
age difference to be present only in seminomas. In non-
seminomas, the familial cases had a higher age at
orchiectomy than did the sporadic cases. If our finding of
no difference in age of onset is correct, it may imply that the
genetic factor(s) of importance, at least for non-seminomas,
does not follow the Knudson two-hit model and thus that the
gene(s) involved is not a classical tumour-suppressor gene.
However, there may be other explanations for our findings.
In particular, since TC affects young men who have not
completed their reproductive period, complex mechanisms
leading to ascertainment bias may be present.
The prevalence of UDT in the familial cases was not
different from that of the sporadic cases. Taken together with
data from the literature (Forman et al., 1992; Tollerud et al.,
1985), this suggests that the risk from being related to a TC
patient is not dependent on the risk conferred by UDT.
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